Open company graph database — free web & API
Login

Nippon Organ Pharmaceutical Co., Ltd.

日本臓器製薬株式会社
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
7
§01

Basic information

BASIC
Head office
4-2-3 Hiranocho, Chuo-ku, Osaka, 541-0046
Chief executive
Takafumi Konishi
Capital
100,000,000 JPY
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

2
Medical drugsOver-the-counter drugs
§04

Related companies

7 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Japan Organs Vietnam Limited Company
Group
BSM Inc.
Group
Zett株式会社
Group
上海小西生物技术有限公司
Group
小西医药信息咨询(北京)有限公司
Group
小西越南生物技术有限会社
Group
日本ALS株式会社
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

89 EVENTS

Founded the Japan Organ Research Institute in Setono-ku, Osaka (representative: Mr. Gai Jiro Katsu).Sources

Founded in Setono-ku, Osaka City, the company Dainippon Organ Research Institute Co., Ltd. (represented by Mr. Seikane Gijiro).Sources

Relocated headquarters and factory to Hirano-ku, Osaka.Sources

Relocated headquarters and factory to Hirano-ku, Osaka City.Sources

Established the Japan Organ Physiology Research Institute for allergy disease research and treatment.Sources

Established the Japan Organ Physiology Research Institute to study and treat allergic diseases.Sources

Mr. Konishi Jin-Ōemon joined as an advisor.Sources

Mr. Koyoshi Jin'go served as a senior advisor in management.Sources

Mr. Jiro Sugano became president.Sources

Mr. Jiro Sugano appointed president.Sources

Ended the exclusive agency agreement with Yoshino Pharmaceutical Co., Ltd. and began self-selling of products.Sources

Successfully terminated the exclusive distribution contract with Yamano Pharmaceutical Co., Ltd. and began independent product sales.Sources

Renamed the company to Nippon Organ Pharmaceutical Co., Ltd.Sources

Changed company name to Japan Organ Pharmaceutical Co., Ltd.Sources

Mr. Konishi Jin-Ōemon, as an advisor, became president.Sources

Senior advisor Mr. Koyoshi Jin'go appointed president.Sources

Established a business partnership with BioVazaar AG (Switzerland) and Promedica SA (France).Sources

Established business cooperation with Biobasal in Switzerland and Promedica in France.Sources

Proposed the first Japan-France Allergy Conference and held it at the University of Paris. Subsequently, it has been held jointly every three years.Sources

Advocated and held the first Japan-France Allergy Conference at the University of Paris. Subsequently, it is held every three years alternately in Japan and France.Sources

Established Japan AeroPure for the manufacture and sale of the air pollution prevention device AeroPure®.Sources

Established Japan Aeropur to manufacture and sell Aeropur® devices that prevent atmospheric pollution.Sources

Released a new 3cc vial of Neurotropon®.Sources

Neurotropin® 3cc launched.Sources

Held the first Japan-China Immunoallergy Conference in Beijing and Shanghai.Sources

Held the first Japan-China Immunology Allergy Conference in Beijing and Shanghai.Sources

Established the China-Japan Hematology Immunology Research Center in Shanghai through Sino-Japanese cooperation.Sources

Established the Japan-China Hematology Immunology Research Center in Shanghai through Japan-China cooperation for basic medical exchange and talent development.Sources

Completion of the Institute of Bioactive Science.Sources

Completion of the Institute of Bioactive Science.Sources

Established the Konishi International Exchange Foundation, approved by the Minister of Foreign Affairs.Sources

Established the Koyoshi International Exchange Foundation with the approval of the Minister of Foreign Affairs.Sources

Held the first Japan-South Korea-Bulgaria Emotional Stress Conference at the International Conference Hall of the Institute of Bioactive Science.Sources

The 1st Japan-Soviet Union-Bulgaria Emotional Stress Conference was held in the International Conference Hall of the Institute of Bioactive Sciences.Sources

Held the first Japan-France China Immunoallergy Conference in Beijing and Shanghai.Sources

The 1st Japan-France-China Immunologic Allergy Conference (6th Japan-France Allergy Conference, 5th Japan-China Immunologic Allergy Conference) was held in Beijing and Shanghai.Sources

The Institute of Bioactive Science received the Green Architecture Award for the Hyogo Prefecture-wide park greening project.Sources

The Institute of Bioactive Sciences received the "Green Building Award" for the Hyogo Prefecture-wide Park Greening Concept.Sources

Ono Green Garden Factory completion.Sources

Established the Japan Organ Self-Defense Group under the principle of "protecting one's own company".Sources

The Kono Green Park Factory was completed.Sources

The first Sino-Japanese collaborative Shanghai International Medical Seminar was held in Shanghai.Sources

The 1st Japan-China Cooperation Shanghai International Medical Symposium was held in Shanghai.Sources

New release of Nirotropin® tablets.Sources

Neurotropin® tablets were launched.Sources

The 7th Japan-France Allergy Conference (20th anniversary commemorative conference) was held in Clé Boujou.Sources

The 7th Japan-France Allergy Conference was held in France (20th Anniversary Commemorative Conference).Sources

Established Beijing office.Sources

The Beijing Representative Office was established.Sources

Joint venture between Japan and China, Shanghai Xiaoxi Biotechnology Co., Ltd. established. Nirotropin® tablets approved for import in China.Sources

The Japan-China joint venture – Shanghai Xiaoxi Biotechnology Co., Ltd. was established.Sources

Nirotropin® Special 3cc approved for import in China.Sources

Neurotropin® tablets were approved for import in China.Sources

Completion of the Technology Research Institute.Sources

The Technology Institute was completed.Sources

Established Xiaoxi South Carolina Medical University Inflammation Research Institute.Sources

The Xiaoxi South Carolina Medical University Inflammation Institute was established.Sources

Xiaoxi Ryusaku appointed as president.Sources

Mr. Xiaoxi Longzuo was appointed president.Sources

The Representative Office in the United States was opened.Sources

Completion of Xinghuo factory of Shanghai Xiaoxi Biotechnology Co., Ltd.Sources

The Starfire Factory of Shanghai Xiaoxi Biotechnology Co., Ltd. was completed.Sources

Completion of second manufacturing building of Ono Midori Garden Factory.Sources

The 2nd Manufacturing Building of the Kono Green Park Factory was completed.Sources

The new Research Building of the Institute of Bioactive Sciences was completed.Sources

Completion of the Pharmaceutical Research Institute Building.Sources

The Formulation Institute building was completed.Sources

The new factory of Qingdao Xiaoxi Biotechnology Co., Ltd. is under construction.Sources

Completion of raw material related facility in Vietnam.Sources

The New Zealand White Rabbit Farm was completed in Vietnam.Sources

Relocate the first and second branches in Tokyo to the company's headquarters in Chiyoda-ku, Tokyo.Sources

Established Xiaoxi Pharmaceutical Information Consulting (Beijing) Co., Ltd.Sources

Establish Xiao Xi Medical Information Consulting (Beijing) Co., Ltd.Sources

Established Xiaoxi Vietnam Biotechnology Co., Ltd.Sources

Establish Xiao Xi Vietnam Biotechnology Co., Ltd.Sources

Established Japan Organ Vietnam Co., Ltd.Sources

Establish Japan Organ Vietnam Co., Ltd.Sources

Japan Organ Vietnam Co., Ltd. completed phase 1 construction of raw material related facility in Yen Bai province.Sources

Japan Organ Vietnam Co., Ltd. completed the first phase of the rabbit house project in An Phe Province.Sources

Acquisition of Type 1 Medical Device Manufacturing and Sales License.Sources

Obtain the license for manufacturing and selling the first type of medical device.Sources

Relocated headquarters to 4-chome, Hirano-cho, Chuo-ku, Osaka City.Sources

Relocate the headquarters to 4-4 Hiranocho, Chuo-ku, Osaka City.Sources

Xiaoxi Takafumi appointed as president.Sources

Mr. Xiao Xi Zongwen assumes the position of president.Sources

Established ZSpine Co., Ltd., which introduces and sells orthopedic medical devices in Japan.Sources

ZSpine Co., Ltd. launched NOVOMAX® FUSION spinal cage.Sources

Signed a license agreement with Serve BioPharma Inc. regarding the oncolytic virus "Surv.m-CRA-1".Sources

Signed a domestic supply agreement with Jazz Pharmaceuticals for cannabinoid pharmaceutical.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information4120001077617
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
日本臓器製薬株式会社
Trade name (kana)
ニッポンゾウキセイヤク
Name in English
Nippon Zoki Pharmaceutical Co.,Ltd.
Corporation type
301
Address
〒541-0046 大阪府大阪市中央区平野町4丁目2番3号
Postal code
5410046
Prefecture code
27
City code
128
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2025-08-25
Change date
2020-08-04
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
1
Trade name image ID
Address image ID
Sequence number
4148283
METI gBizINFO4120001077617
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
4120001077617
Trade name
日本臓器製薬株式会社
Trade name (kana)
ニホンゾウキセイヤク
Trade name (alphabet)
Nippon Zoki Pharmaceutical Co.,Ltd.
Registry closure date
Reason for registry closure
Registered address
大阪府大阪市中央区平野町4丁目2番3号
Postal code
5410046
Prefecture
大阪府
Prefecture code
27
City or district
大阪市中央区
City code
128
Street address
平野町4丁目2番3号
Organisation type
301
Processing type
12
Correction type
1
Status
Representative
Capital
Employees
577
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2026-07-06
Key information
4120001077617
§09

Sources & updates

SOURCES
↑